MarginsXMarginsX
Home › Markets › Health Care › RZLT

Rezolute Inc. Common Stock (NV) (RZLT)

RZLT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.58
-2.05% on the day
Market cap
$346.3M
Small cap
Revenue
Not reported in SEC XBRL data
Net income
Not reported in SEC XBRL data

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.

Profile

FieldValue
TickerRZLT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001509261
SEC industry codePharmaceutical Preparations
Incorporated inNV

Financials

Not reported in SEC XBRL data.

Warning signs

Cash runway
1.5 months
$8.2M cash at September 30, 2026
Share count, 1 year
+4.3%
2025-11-04 to 2026-11-02 · +144.1% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$231K
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$8.2M cash; operating cash flow -$16.5M a quarter.Report 2026-09-30
Shares outstanding96,728,913 (2026-11-02); 92,727,532 a year earlier; 39,625,271 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-11-13
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton LLP, Newport Beach, California, United StatesPCAOB Form AP 2026-10-07
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $231K, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q1 2027
2026-09-30
Not filed-$18.5M-$18.8M$8.2MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2026
2026-06-30
Not filed-$20.5M-$13.1M$10.6MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q3 2026
2026-03-31
Not filed-$16.2M-$13.7M$11.2MNo debt tagsNeeds four quarters10-Q 2026-05-12
Q2 2026
2025-12-31
Not filed-$22.8M-$20.3M$11.9MNo debt tagsNeeds four quarters10-Q 2026-02-12
Q1 2026
2025-09-30
Not filed-$18.1M-$17.4M$9.1MNo debt tagsNeeds four quarters10-Q 2026-11-05
Q4 2025
2025-06-30
Not filed-$24.4M-$22.0M$94.1MNo debt tagsNeeds four quarters10-K 2026-09-24
Q3 2025
2025-03-31
Not filed-$18.9M-$17.4M$14.6MNo debt tagsNeeds four quarters10-Q 2026-05-12
Q2 2025
2024-12-31
Not filed-$15.7M-$13.7M$8.9MNo debt tagsNeeds four quarters10-Q 2026-02-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52026-11-16
Latest annual report10-K2026-09-24
Latest quarterly / interim10-Q2026-11-05
Latest current report
FORM 8-K
8-K2026-11-16
Latest proxyDEF 14A2026-10-21

Source: SEC EDGAR submissions feed, 767 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-5.8%
1 month-20.7%
3 months-20.5%
Year to date+54.9%
1 year-63.2%
From 52-week high-66.6%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ASPEAspen Neuroscience Inc.$12.23-2.86%$355.6M
SPRYARS Pharmaceuticals Inc.$3.59-7.71%$360.9M
AVIRAtea Pharmaceuticals Inc.$4.12-4.19%$330.9M
PBYIPuma Biotechnology Inc$7.34-5.53%$379.5M
CTNMContineum Therapeutics Inc.$9.67-1.93%$379.7M
CRMDCorMedix Inc.$4.82+3.43%$383.4M
LRMRLarimar Therapeutics Inc.$3.00-0.66%$311.6M
RLMDRelmada Therapeutics Inc.$3.61-14.25%$385.2M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier